| The safety and efficacy (effectiveness) of treatment with Betaseron
® beyond 3 years is not known. The safety and efficacy
(effectiveness) of Betaseron ® in patients with chronic progressive
multiple sclerosis have not been established.
The safety and efficacy (effectiveness) of Betaseron ®
in pediatric patients under the age of 18 years have not been evaluated.
It is unknown whether patients over the age of 65 years respond differently
to Betaseron ® than younger patients.
It is unknown whether Betaseron ® can affect human reproductive
capacity.
|
